BGC-20-1531 (PGN 1531) free base is a potent and selective prostanoid EP 4 receptor antagonist, with a pK B of 7.6. BGC-20-1531 free base has the potential for the research of migraine headache In Vitro BGC-20-1531 free base competitively antagonized PGE 2 -induced vasodilatation of human middle cerebral (pK b =7.8) and meningeal (pK b =7.6) arteries, but had no effect on responses induced by PGE 2 on coronary, pulmonary or renal arteries. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo BGC-20-1531 free base (1-10 mg/kg; i.v.) causes a dose-dependent antagonism of the PGE 2 -induced increase in canine carotid blood flow . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Beagle dogs Dosage: 1-10 mg/kg Administration: I.v. Result: Caused a dose-dependent antagonism of the PGE 2 -induced increase in canine carotid blood flow. Form:Solid IC50& Target:EP4 7.6 (pKd)